Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261


The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer.

Kaderbhaï C, Tharin Z, Ghiringhelli F.

Cancers (Basel). 2019 Feb 10;11(2). pii: E201. doi: 10.3390/cancers11020201. Review.


Nouvelles stratégies innovantes en immunothérapie.

Ghiringhelli F.

Bull Cancer. 2018 Dec;105 Suppl 1:S101-S112. doi: 10.1016/S0007-4551(18)30395-3. Review. French.


The Direct Conversion of α-Hydroxyketones to Alkynes.

Ghiringhelli F, Nattmann L, Bognar S, van Gemmeren M.

J Org Chem. 2018 Dec 19. doi: 10.1021/acs.joc.8b02941. [Epub ahead of print]


Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer.

Ghiringhelli F, Truntzer C.

Oncotarget. 2018 Nov 27;9(93):36547-36548. doi: 10.18632/oncotarget.26389. eCollection 2018 Nov 27. No abstract available.


RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer.

Ledys F, Klopfenstein Q, Truntzer C, Arnould L, Vincent J, Bengrine L, Remark R, Boidot R, Ladoire S, Ghiringhelli F, Derangere V.

J Immunother Cancer. 2018 Nov 19;6(1):123. doi: 10.1186/s40425-018-0438-3.


Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.

Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, Borel C, François E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C.

JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4465. [Epub ahead of print]


Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F.

Br J Cancer. 2018 Oct;119(8):950-960. doi: 10.1038/s41416-018-0220-9. Epub 2018 Oct 15.


Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.

Collot T, Fumet JD, Klopfenstein Q, Vincent J, Bengrine L, Ghiringhelli F.

Anticancer Res. 2018 Oct;38(10):5963-5968. doi: 10.21873/anticanres.12943.


A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J.

Oncologist. 2018 Sep 28. pii: theoncologist.2018-0290. doi: 10.1634/theoncologist.2018-0290. [Epub ahead of print]


Transcriptional Programs Underlying Cd4 T Cell Differentiation and Functions.

Chalmin F, Humblin E, Ghiringhelli F, Végran F.

Int Rev Cell Mol Biol. 2018;341:1-61. doi: 10.1016/bs.ircmb.2018.07.002. Epub 2018 Aug 20.


FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer.

Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, de Gramont A, Chibaudel B.

World J Clin Oncol. 2018 Sep 14;9(5):110-118. doi: 10.5306/wjco.v9.i5.110.


LPCAT2 controls chemoresistance in colorectal cancer.

Cotte AK, Aires V, Ghiringhelli F, Delmas D.

Mol Cell Oncol. 2018 Apr 11;5(3):e1448245. doi: 10.1080/23723556.2018.1448245. eCollection 2018.


Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study.

Isambert N, Hervieu A, Rébé C, Hennequin A, Borg C, Zanetta S, Chevriaux A, Richard C, Derangère V, Limagne E, Blanc J, Bertaut A, Ghiringhelli F.

Oncoimmunology. 2018 Aug 1;7(9):e1474319. doi: 10.1080/2162402X.2018.1474319. eCollection 2018.


Secondary findings from whole-exome/genome sequencing evaluating stakeholder perspectives. A review of the literature.

Delanne J, Nambot S, Chassagne A, Putois O, Pelissier A, Peyron C, Gautier E, Thevenon J, Cretin E, Bruel AL, Goussot V, Ghiringhelli F, Boidot R, Tran Mau-Them F, Philippe C, Vitobello A, Demougeot L, Vernin C, Lapointe AS, Bardou M, Luu M, Binquet C, Lejeune C, Joly L, Juif C, Baurand A, Sawka C, Bertolone G, Duffourd Y, Sanlaville D, Pujol P, Geneviève D, Houdayer F, Thauvin-Robinet C, Faivre L.

Eur J Med Genet. 2018 Aug 28. pii: S1769-7212(18)30122-8. doi: 10.1016/j.ejmg.2018.08.010. [Epub ahead of print] Review.


Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.

Richard C, Fumet JD, Chevrier S, Derangère V, Ledys F, Lagrange A, Favier L, Coudert B, Arnould L, Truntzer C, Boidot R, Ghiringhelli F.

Clin Cancer Res. 2019 Feb 1;25(3):957-966. doi: 10.1158/1078-0432.CCR-18-1940. Epub 2018 Aug 28.


Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C.

Lancet Oncol. 2018 Aug;19(8):1094-1106. doi: 10.1016/S1470-2045(18)30321-8. Epub 2018 Jul 2.


Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients.

Manfroi B, Moreaux J, Righini C, Ghiringhelli F, Sturm N, Huard B.

Blood Cancer J. 2018 Jul 5;8(7):66. doi: 10.1038/s41408-018-0099-y. No abstract available.


Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.

Fumet JD, Isambert N, Hervieu A, Zanetta S, Guion JF, Hennequin A, Rederstorff E, Bertaut A, Ghiringhelli F.

ESMO Open. 2018 Jun 19;3(4):e000375. doi: 10.1136/esmoopen-2018-000375. eCollection 2018.


Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma.

Aarnink A, Richard C, Truntzer C, Vincent J, Bengrine L, Vienot A, Borg C, Ghiringhelli F.

Oncotarget. 2018 May 22;9(39):25617-25629. doi: 10.18632/oncotarget.25424. eCollection 2018 May 22.


PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.

Dosset M, Vargas TR, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Lauret Marie-Joseph E, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L.

Oncoimmunology. 2018 Mar 15;7(6):e1433981. doi: 10.1080/2162402X.2018.1433981. eCollection 2018.


Reply to M. Mo et al.

Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bennouna J.

J Clin Oncol. 2018 Aug 10;36(23):2452-2453. doi: 10.1200/JCO.2018.78.9669. Epub 2018 Jun 4. No abstract available.


[Novel strategy in oncoimmunology].

Ghiringhelli F.

Bull Cancer. 2018 Apr 25. pii: S0007-4551(18)30114-0. doi: 10.1016/j.bulcan.2018.03.004. [Epub ahead of print] Review. French.


Imidazo[2,1-b]benzothiazol Derivatives as Potential Allosteric Inhibitors of the Glucocorticoid Receptor.

Christodoulou MS, Dapiaggi F, Ghiringhelli F, Pieraccini S, Sironi M, Lucafò M, Curci D, Decorti G, Stocco G, Chirumamilla CS, Vanden Berghe W, Balaguer P, Michel BY, Burger A, Beccalli EM, Passarella D, Martinet N.

ACS Med Chem Lett. 2018 Feb 26;9(4):339-344. doi: 10.1021/acsmedchemlett.7b00527. eCollection 2018 Apr 12.


EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma.

Richard C, Niogret J, Boidot R, Ghiringhelli F.

World J Gastrointest Oncol. 2018 Apr 15;10(4):103-107. doi: 10.4251/wjgo.v10.i4.103.


Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER.

J Clin Oncol. 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5.


Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial.

Fumet JD, Bertaut A, Bengrine L, Lapierre P, Vincent J, Ghiringhelli F, Falvo N.

Oncotarget. 2017 Dec 1;9(16):12599-12608. doi: 10.18632/oncotarget.22822. eCollection 2018 Feb 27.


5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.

Morawska K, Goirand F, Marceau L, Devaux M, Cueff A, Bertaut A, Vincent J, Bengrine-Lefevre L, Ghiringhelli F, Schmitt A.

Oncotarget. 2018 Jan 30;9(14):11559-11571. doi: 10.18632/oncotarget.24338. eCollection 2018 Feb 20.


Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Reyes-Botero G, Cartalat-Carel S, Chinot OL, Barrie M, Taillandier L, Beauchesne P, Catry-Thomas I, Barrière J, Guillamo JS, Fabbro M, Frappaz D, Benouaich-Amiel A, Le Rhun E, Campello C, Tennevet I, Ghiringhelli F, Tanguy ML, Mokhtari K, Honnorat J, Delattre JY.

Oncologist. 2018 May;23(5):524-e44. doi: 10.1634/theoncologist.2017-0689. Epub 2018 Feb 22.


Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study.

Mirjolet C, Charon-Barra C, Ladoire S, Arbez-Gindre F, Bertaut A, Ghiringhelli F, Leroux A, Peiffert D, Borg C, Bosset JF, Créhange G.

Oncoimmunology. 2017 Nov 27;7(3):e1396402. doi: 10.1080/2162402X.2017.1396402. eCollection 2018.


Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.

Cotte AK, Aires V, Fredon M, Limagne E, Derangère V, Thibaudin M, Humblin E, Scagliarini A, de Barros JP, Hillon P, Ghiringhelli F, Delmas D.

Nat Commun. 2018 Jan 22;9(1):322. doi: 10.1038/s41467-017-02732-5.


Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Jacquot S, Genet D, Khemissa F, Suc E, Desseigne F, Texereau P, Lepage C, Bennouna J; PRODIGE 9 Investigators.

J Clin Oncol. 2018 Mar 1;36(7):674-681. doi: 10.1200/JCO.2017.75.2931. Epub 2018 Jan 18.


IRF8-dependent molecular complexes control the Th9 transcriptional program.

Humblin E, Thibaudin M, Chalmin F, Derangère V, Limagne E, Richard C, Flavell RA, Chevrier S, Ladoire S, Berger H, Boidot R, Apetoh L, Végran F, Ghiringhelli F.

Nat Commun. 2017 Dec 12;8(1):2085. doi: 10.1038/s41467-017-01070-w.


Protective effects of polyphenol-rich infusions from carob (Ceratonia siliqua) leaves and cladodes of Opuntia ficus-indica against inflammation associated with diet-induced obesity and DSS-induced colitis in Swiss mice.

Aboura I, Nani A, Belarbi M, Murtaza B, Fluckiger A, Dumont A, Benammar C, Tounsi MS, Ghiringhelli F, Rialland M, Khan NA, Hichami A.

Biomed Pharmacother. 2017 Dec;96:1022-1035. doi: 10.1016/j.biopha.2017.11.125. Epub 2017 Dec 6.


Correction: Novel chemical probes for the investigation of nonribosomal peptide assembly.

Ho YTC, Leng DJ, Ghiringhelli F, Wilkening I, Bushell DP, Kostner O, Riva E, Havemann J, Passarella D, Tosin M.

Chem Commun (Camb). 2017 Nov 16;53(92):12481. doi: 10.1039/c7cc90432k.


Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.


Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer.

Kaderbhai CG, Richard C, Fumet JD, Aarnink A, Ortiz-Cuaran S, Pérol M, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ladoire S, Poudenx M, Ilie M, Hofman P, Saintigny P, Ghiringhelli F.

Oncoimmunology. 2017 Jun 16;6(9):e1339856. doi: 10.1080/2162402X.2017.1339856. eCollection 2017.


The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.

Marisa L, Svrcek M, Collura A, Becht E, Cervera P, Wanherdrick K, Buhard O, Goloudina A, Jonchère V, Selves J, Milano G, Guenot D, Cohen R, Colas C, Laurent-Puig P, Olschwang S, Lefèvre JH, Parc Y, Boige V, Lepage C, André T, Fléjou JF, Dérangère V, Ghiringhelli F, de Reynies A, Duval A.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx136.


Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells.

Rivera Vargas T, Cai Z, Shen Y, Dosset M, Benoit-Lizon I, Martin T, Roussey A, Flavell RA, Ghiringhelli F, Apetoh L.

Nat Commun. 2017 Sep 15;8(1):559. doi: 10.1038/s41467-017-00468-w.


Immune classifications with cytotoxic CD8+ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.

Madkouri R, Kaderbhai CG, Bertaut A, Truntzer C, Vincent J, Aubriot-Lorton MH, Farah W, Limagne E, Ladoire S, Boidot R, Derangère V, Ghiringhelli F.

Oncoimmunology. 2017 Apr 28;6(6):e1321186. doi: 10.1080/2162402X.2017.1321186. eCollection 2017.


Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.

Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, Le Cesne A, Bompas E, Piperno-Neumann S, Cousin S, Grellety T, Ryckewaert T, Bessede A, Ghiringhelli F, Pulido M, Italiano A.

JAMA Oncol. 2018 Jan 1;4(1):93-97. doi: 10.1001/jamaoncol.2017.1617.


Novel chemical probes for the investigation of nonribosomal peptide assembly.

Ho YTC, Leng DJ, Ghiringhelli F, Wilkening I, Bushell DP, Köstner O, Riva E, Havemann J, Passarella D, Tosin M.

Chem Commun (Camb). 2017 Jun 27;53(52):7088-7091. doi: 10.1039/c7cc02427d.


Precision medicine in breast cancer: reality or utopia?

Bettaieb A, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F.

J Transl Med. 2017 Jun 17;15(1):139. doi: 10.1186/s12967-017-1239-z. Review.


Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

Kaderbhai C, Richard C, Fumet JD, Aarnink A, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ghiringhelli F.

Anticancer Res. 2017 Jun;37(6):3195-3200.


Transcription Factor Binding Studies in CD4+ T Cells: siRNA Transfection, Chromatin Immunoprecipitation, and Liquid Luminescent DNA Precipitation Assay.

Humblin E, Ghiringhelli F, Végran F.

Methods Mol Biol. 2017;1585:167-177. doi: 10.1007/978-1-4939-6877-0_13.


Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Bachet JB, Borg C, Ducreux M, Marcheteau E, Stanbury T, Gourgou S, Malka D, Taieb J.

Eur J Cancer. 2017 Jul;79:15-22. doi: 10.1016/j.ejca.2017.03.036. Epub 2017 Apr 26.


Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation.

Limagne E, Thibaudin M, Euvrard R, Berger H, Chalons P, Végan F, Humblin E, Boidot R, Rébé C, Derangère V, Ladoire S, Apetoh L, Delmas D, Ghiringhelli F.

Cell Rep. 2017 Apr 25;19(4):746-759. doi: 10.1016/j.celrep.2017.04.004.


Correction: Phenolic extract from oleaster (Olea europaea var. Sylvestris) leaves reduces colon cancer growth and induces caspase-dependent apoptosis in colon cancer cells via the mitochondrial apoptotic pathway.

Zeriouh W, Nani A, Belarbi M, Dumont A, de Rosny C, Aboura I, Ghanemi FZ, Murtaza B, Patoli D, Thomas C, Apetoh L, Rébé C, Delmas D, Khan NA, Ghiringhelli F, Rialland M, Hichami A.

PLoS One. 2017 Apr 20;12(4):e0176574. doi: 10.1371/journal.pone.0176574. eCollection 2017.


Alteration in Taste Perception in Cancer: Causes and Strategies of Treatment.

Murtaza B, Hichami A, Khan AS, Ghiringhelli F, Khan NA.

Front Physiol. 2017 Mar 8;8:134. doi: 10.3389/fphys.2017.00134. eCollection 2017. Review.


Phenolic extract from oleaster (Olea europaea var. Sylvestris) leaves reduces colon cancer growth and induces caspase-dependent apoptosis in colon cancer cells via the mitochondrial apoptotic pathway.

Zeriouh W, Nani A, Belarbi M, Dumont A, de Rosny C, Aboura I, Ghanemi FZ, Murtaza B, Patoli D, Thomas C, Apetoh L, Rébé C, Delmas D, Khan NA, Ghiringhelli F, Rialland M, Hichami A.

PLoS One. 2017 Feb 17;12(2):e0170823. doi: 10.1371/journal.pone.0170823. eCollection 2017. Erratum in: PLoS One. 2017 Apr 20;12 (4):e0176574.


[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].

Ladoire S, Derangère V, Arnould L, Thibaudin M, Coudert B, Lorgis V, Desmoulins I, Chaix M, Fumoleau P, Ghiringhelli F.

Ann Pathol. 2017 Feb;37(1):133-141. doi: 10.1016/j.annpat.2016.12.012. Epub 2017 Jan 31. Review. French.


Supplemental Content

Loading ...
Support Center